– Walsh's Commercial Expertise will Benefit Cagent's Efforts to Develop Serranator Market – Cagent Vascular®, a developer of next generation angioplasty balloons using proprietary serration technology, announces Brian Walsh to serve as Chairman of the Board. Brian Walsh has held several executive level positions in cardiovascular and ophthalmology specialties within the medical device industry. Mr.

Read more

WAYNE, Pa.–(BUSINESS WIRE)—Cagent Vascular®, a developer of next generation angioplasty balloons using proprietary serration technology, announced the completion of $11.87 million in Series B funding. The round was led by two strategic investors including one that participated in the Series A financing. Additional participants included Balestier Investments, Ben Franklin Technology Partners1, Synergy Ventures, and other

Read more

Serranator® has achieved regulatory approvals from both FDA and European Medicines Agency, paving way for successful commercialization WAYNE, Pa.–(BUSINESS WIRE)—Cagent Vascular, a developer of next-generation technology for vessel dilatation in cardiovascular disease interventions, announces the issuance of its CE Marking for the Serranator ® PTA Serration Balloon Catheter.  Cagent Vascular has also achieved its ISO 13485 Certification.

Read more

WAYNE, Pa. –(BUSINESS WIRE)–  Cagent Vascular, a developer of next generation technology for vessel dilatation in cardiovascular disease interventions, including the FDA 510(k) cleared Serranator® Alto PTA Serration Balloon Catheter, announces the completion of enrollment in the First-in Human PRELUDE Study. The purpose of this prospective, single-arm, multicenter feasibility study is to show the safety and efficacy

Read more

WAYNE, Pa.–(BUSINESS WIRE)—Cagent Vascular, a developer of next generation technology for vessel dilatation in cardiovascular disease interventions, announces FDA 510(k) Clearance of its lead product, the SerranatorTM Alto PTA Serration Balloon Catheter.   The SerranatorTM is the first of a family of peripheral artery disease (PAD) technologies under development which incorporate proprietary Serration Technology to an angioplasty balloon. “A new

Read more